Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The recommendations result from research by Prof Irene Roberts and Prof Paresh Vyas, published today in the British Journal of Haematology.

© David Gregory & Debbie Marshall (CC BY 4.0)

Research in recent years has revealed that babies with Down Syndrome usually have abnormalities in their blood when they are born. Many of these problems rapidly disappear, but a small number have blood problems that can make them extremely unwell over the first few weeks of life.

The need for routine blood testing

Babies with Down syndrome can suffer from 2 potential conditions. Transient Leukaemia of Down Syndrome affects around 1 in 10 of babies. Of these, 1 in 4 can become seriously ill, and specialised treatment is necessary. In addition to this condition, between 1 in 100 and 1 in 50 children with Down Syndrome can also develop a specialised kind of leukaemia known as Myeloid Leukaemia of Down Syndrome, before their 4th birthday. By comparison, only 1 in 7,000 children without Down Syndrome develop myeloid leukaemia. Early detection and close monitoring of Down syndrome babies is key for a good prognosis. Yet, routine blood testing for leukaemia in these babies only happens in a relatively small number of cases.

New national guidelines

The new British Society for Haematology guidelines published today in the British Journal of Haematology, led by a group including Prof Irene Roberts (Department of Paediatrics) and Prof Paresh Vyas (Radcliffe Department of Medicine) at the MRC Molecular Haematology Unit, recommends that all babies with Down Syndrome should have a blood count and blood film in the first few days of life. This test can be done at the same time as other blood tests, and in most cases, will mean that parents can be reassured. In those cases where the results of these test alert the clinical team of a potential diagnosis, a further genetic test will be conducted, and monitoring will take place to check for any signs of progression into leukaemia.

 

Prof Irene Roberts and Prof Paresh VyasProf Irene Roberts and Prof Paresh Vyas

 

“Until now guidelines for the treatment of children with Down syndrome at risk of developing leukaemia have been vague, implementation has been haphazard and children have been diagnosed late as a result.” Said Prof Roberts “Early intervention greatly increases children’s chances of survival if symptoms do develop, helping to save lives.”.

 “A simple test can ensure that those children at risk of cancer are put under the care of a specialist paediatrician. They are properly monitored and are treated straight away when symptoms develop.” Said Prof Vyas “Importantly, it also provides reassurance to the parents of those children not at risk, removing the fear and worry of leukaemia for many families.”

These new clinical guidelines are the result of years of research and clinical studies, funded by the charities Bloodwise and Children with Cancer UK. Written by expert consultants and clinical scientists currently practising in the UK, British Society of Haematology guidelines provide up-to-date evidence-based guidance on the diagnosis and treatment of haematological diseases.

 

Similar stories

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.